

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER 22215 26th Ave SE Suite 210 Bothell, WA 98021 (425)302-0340 Fax: (425)302-0404		DATE(S) OF INSPECTION 8/28/2018-4/25/2019* FEI NUMBER 3014549846
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Amy A. Frost, Pharmacist-in-Charge		
FIRM NAME Pinnacle Compounding	STREET ADDRESS 1120 Kensington Ave Unit E	
CITY, STATE, ZIP CODE, COUNTRY Missoula, MT 59801-5619	TYPE ESTABLISHMENT INSPECTED Compounding Pharmacy	
<p>This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.</p>		
<p>DURING AN INSPECTION OF YOUR FIRM WE OBSERVED: OBSERVATION 1 (b) (4) intended to render final product sterile was not adequate to accomplish sterilization.</p> <p>Specifically,</p> <p>a. Your firm failed to conduct (b) (4) testing on (b) (4) used to sterilize Atropine Sulfate 0.01% Sterile Ophthalmic Solution, lot 021219OS1010, manufactured on 02/12/19, with a beyond-use date (BUD) of 180 days.</p> <p>b. Your firm released products purported to be sterile despite the failure of the (b) (4) used in their production to meet the manufacturer's (b) (4) test specifications. For example:</p> <ul style="list-style-type: none"> • Prednisolone/Ketorolac 1%/0.5% Ophthalmic Solution, lot 021319OS1001, manufactured on 02/13/19, with a BUD of 180 days, was released with a (b) (4) testing result of (b) (4) which is below the manufacturer's specification of (b) (4) • Timolol/Brimonidine/Dozolamide 0.5%/0.2%/2% Ophthalmic Solution, lot 02072019OS1006, manufactured on 02/07/19, with a BUD of 180 days, was released with a (b) (4) testing result of (b) (4) which is below the manufacturer's specification of (b) (4) 		
<p>*DATES OF INSPECTION 8/28/2018(Tue), 8/29/2018(Wed), 8/30/2018(Thu), 8/31/2018(Fri), 9/04/2018(Tue), 9/05/2018(Wed), 9/06/2018(Thu), 9/07/2018(Fri), 4/17/2019(Wed), 4/18/2019(Thu), 4/25/2019(Thu)</p>		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Christopher R Czajka, Investigator Andrew K Haack, Generic Drug User Fee Amendments (GDUFA)	DATE ISSUED 4/25/2019
	Andrew K Haack Generic Drug User Fee Amendments (GDUFA) Signed: Dr. Andrew K. Haack -3 Date Signed: 04-25-2019 10:48:05 X	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS
		PAGE 1 of 2 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER 22215 26th Ave SE Suite 210 Bothell, WA 98021 (425)302-0340 Fax:(425)302-0404		DATE(S) OF INSPECTION 8/28/2018-4/25/2019*	
		FEI NUMBER 3014549846	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Amy A. Frost, Pharmacist-in-Charge			
FIRM NAME Pinnacle Compounding		STREET ADDRESS 1120 Kensington Ave Unit E	
CITY, STATE, ZIP CODE, COUNTRY Missoula, MT 59801-5619		TYPE ESTABLISHMENT INSPECTED Compounding Pharmacy	
<p style="margin-left: 100px;"> X Christopher R Czajka Investigator Signed By: Christopher R. Czajka -S Date Signed: 04-25-2019 10:46:37 </p>			
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Christopher R Czajka, Investigator Andrew K Haack, Generic Drug User Fee Amendments (GDUFA)		DATE ISSUED 4/25/2019
			<p style="font-size: small;"> Andrew K Haack Generic Drug User Fee Amendments (GDUFA) Signed By: Andrew K. Haack -S Date Signed: 04-25-2019 10:46:05 </p> <p style="font-size: x-large; margin-left: 10px;">X</p>
FORM FDA 483 (09/08)		PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS
			PAGE 2 of 2 PAGES